Skip to main content

Search

Reset all filters
136 Result(s)
Sort by

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV

Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV
Pommeraie collaborative COPD strategy

Pommeraie collaborative COPD strategy

La Pommeraie's Collaborative COPD Strategy, with Boehringer Ingelheim Canada's Patient Access division, focuses on enhancing COPD patients' health and reducing hospitalizations.
CONTINUUM

CONTINUUM

CONTINUUM, a collaborative project, investigates how digital technology can help healthcare professionals manage complex patient cases at home. Keep reading.
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD

New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD

Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
ABILD

ABILD

ABILD partnership aims at enhancing health innovation projects to comprehend care gaps in diagnosis, treatment, and access for Albertans with progressive fibrosing ILD.